Joaquim Bellmunt, MD, PhD

Articles

Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor Burden

June 18th 2024

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Dr Bellmunt on Predictive Signatures for Checkpoint Inhibitor Responses in Urothelial Cancer

June 11th 2024

Joaquim Bellmunt, MD, PhD, discusses the predictive value of H3K27ac epigenomic and single-cell transcriptional profiling in urothelial cancer.

Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma

May 13th 2024

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 2nd 2024

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer

April 5th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.

Dr. Bellmunt on Immunotherapy Combination Trials in Bladder Cancer

March 28th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses trials investigating combinations with immunotherapy for patients with bladder cancer.

Dr. Bellmunt on PD-L1 Data in Bladder Cancer

March 13th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses PD-L1 data with pembrolizumab (Keytruda) in patients with bladder cancer.

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

February 20th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

Dr. Bellmunt on Immunotherapy Plus IDO in Urothelial Carcinoma

February 12th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses the combination of immunotherapy with IDO inhibitors for patients with urothelial carcinoma.

Dr. Bellmunt Discusses Follow-Up Data for Pembrolizumab vs Chemotherapy in Bladder Cancer

February 10th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses 2-year follow-up results from the phase III KEYNOTE-045 trial of pembrolizumab (Keytruda) versus chemotherapy in recurrent, advanced urothelial carcinoma during the 2018 Genitourinary Cancers Symposium.

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer

November 13th 2016

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC

March 3rd 2014

A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.